Contact
/
Home
/
About
Team
Portfolio
Exit History
News
About
Team
Portfolio
Exit History
News
Advent Life Sciences
Advent Life Sciences
Page 1 of 24
<< Start
< Prev
1
2
3
4
5
6
7
8
9
10
Next >
End >>
16.05.2022
Shionogi & Co., Ltd. and F2G Ltd., Enter Strategic Collaboration to Develop and Commercialize the New Antifungal Agent Olorofim in Europe and Asia
Press Release
11.05.2022
Artax Biopharma Closes Financing to Advance Clinical Stage First-in- Class Oral Immunomodulator to Treat T Cell-Mediated Diseases
Press Release
04.05.2022
Amphista Therapeutics Enters Strategic Collaboration with Merck for Discovery and Development of Targeted Protein Degradation Therapeutics
Press Release
04.05.2022
Amphista Therapeutics Enters Strategic Collaboration with Bristol Myers Squibb for Discovery and Development of Targeted Protein Degradation Therapeutics
Press Release
04.05.2022
AviadoBio to Present Pre-clinical Data on its Gene Therapy Candidate for Frontotemporal Dementia at ASGCT 2022
Press Release
03.05.2022
Aura Biosciences Presents Preclinical Data Highlighting AU-011’s Anti-Tumor Activity in Choroidal Metastasis, an Additional Ocular Oncology Indication at the 2022 ARVO Annual Meeting
Press Release
02.05.2022
Orphalan announces FDA approval of Cuvrior™ for the treatment of adult patients with stable Wilson’s disease who are de-coppered and tolerant to penicillamine
Press Release
27.04.2022
ARGÁ MEDTECH SHOWS PROMISE FOR NEW CARDIAC ABLATION TECHNOLOGY AT 2022 HEART RHYTHM SOCIETY ANNUAL MEETING
Press Release
25.04.2022
Novel CryptigenTM technology unlocks full potential of Tumour Specific Antigens
Press Release
14.04.2022
Highlight Therapeutics announces follow-up results from Phase 2b study of BO-112 + anti-PD1 in confirmed anti-PD1 progressor melanoma patients at AACR
Press Release
©2022 Advent Life Sciences